Full Text Journal Articles by
Author Darren K McGuire

Advertisement

Find full text journal articles






Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58.

Thomas A Zelniker, David A Morrow, Ofri Mosenzon, Erica L Goodrich, Petr Jarolim, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding, Christoph Bode, Basil S Lewis, Ingrid Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Itamar Raz, Marc S Sabatine, Stephen D Wiviott,

<b>Aims: </b>Dapagliflozin reduced the risk of the composite of cardiovascular death or hospitalization for heart failure (CV death/HHF) in patients with type 2 diabetes (T2DM) in DECLARE-TIMI 58. We hypothesized that baseline NT-proBNP and hsTnT levels would help identify patients who are at higher baseline risk and we describe the ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod, David Z I Cherney, Jamie P Dwyer, Benjamin M Scirica, Clifford J Bailey, Rafael Díaz, Kausik K Ray, Jacob A Udell, Renato D Lopes, Pablo Lapuerta, P Gabriel Steg, ,

BACKGROUND:The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS:We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Gradient of Risk and Associations with Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function: Observations from VERTIS CV.

David Z I Cherney, Darren K McGuire, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P Cannon,

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes.

Michael C Honigberg, Ravi B Patel, Ambarish Pandey, Gregg C Fonarow, Javed Butler, Darren K McGuire, Muthiah Vaduganathan,

JAMA Cardiol (JAMA cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Prevention of CV outcomes in antihyperglycaemic drug-naïve patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin.

Naveed Sattar, Darren K McGuire,

Eur Heart J (European heart journal)
[2020, :]

Cited: 0 times

View full text PDF listing >>



SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl, Leigh Perreault, Sylvia E Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic,

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose ... Read more >>

Diabetes (Diabetes)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.

Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes, Marat Fudim,

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with improved cardiovascular and kidney outcomes. However, the magnitude and potential heterogeneity of effect across patients with varying types of cardiometabolic and kidney disease is unclear. To examine the effect of SGLT2i on cardiovascular and kidney outcomes among patients with type 2 ... Read more >>

Am Heart J (American heart journal)
[2020, 232:10-22]

Cited: 0 times

View full text PDF listing >>



SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl, Leigh Perreault, Sylvia E Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic,

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose ... Read more >>

Am J Kidney Dis (American journal of kidney diseases : the official journal of the National Kidney Foundation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato D Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt, ,

BACKGROUND:Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown. METHODS:We performed a multicenter, double-blind trial ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Recognized Outstanding Reviewers for Circulation in 2020.

Joseph A Hill, James A de Lemos, Darren K McGuire, ,

Circulation (Circulation)
[2020, 142(20):1885-1886]

Cited: 0 times

View full text PDF listing >>



Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

Stephen J Nicholls, A Michael Lincoff, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian, Paul M Ridker, Kausik K Ray, Brian G Katona, Anders Himmelmann, Larrye E Loss, Martin Rensfeldt, Torbjörn Lundström, Rahul Agrawal, Venu Menon, Kathy Wolski, Steven E Nissen,

Importance:It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk. Objective:To determine the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia ... Read more >>

JAMA (JAMA)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials.

Anna Plitt, Thomas A Zelniker, Jeong-Gun Park, Darren K McGuire, Christian T Ruff, Elliott M Antman, Eugene Braunwald, Robert P Giugliano,

AIMS:Concomitant atrial fibrillation (AF) and diabetes mellitus (DM) increases risk of stroke and systemic embolic events. This meta-analysis assessed the benefit/risk balance of non-vitamin K antagonist oral anticoagulants (NOACs) vs warfarin, and explored whether there was effect modification by DM or heterogeneity in outcomes between NOACs in patients with and ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial.

Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen,

AIMS:Safety is a key consideration for glucose-lowering agents for older people with type 2 diabetes, yet comparative data are limited. We compared the cardiovascular (CV) safety of linagliptin with glimepiride in older and younger participants in the CAROLINA trial in both pre-specified and post-hoc analyses. MATERIALS AND METHODS:People aged 40-85 years ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck, Ira Gantz, Steven G Terra, Urszula Masiukiewicz, Christopher P Cannon,

Importance:Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. Objective:To perform meta-analyses that assess the CV and kidney outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. Data Sources:A systematic literature search was ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.

Francesco Cosentino, Christopher P Cannon, David Z I Cherney, Urszula Masiukiewicz, Richard Pratley, Sam Dagogo Jack, Robert Frederich, Bernard Charbonnel, James Mancuso, Weichung J Shih, Steven G Terra, Nilo B Cater, Ira Gantz, Darren K McGuire, ,

Background: In patients with type 2 diabetes mellitus (T2DM), sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugliflozin on HHF and related outcomes. Methods: VERTIS CV, a double-blind, placebo-controlled trial, randomized patients with T2DM and atherosclerotic cardiovascular (CV) disease ... Read more >>

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Two Tales: One Story. EMPEROR-Reduced and DAPA-HF.

Subodh Verma, Darren K McGuire, Mikhail N Kosiborod,

Circulation (Circulation)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.

Muhammad Shahzeb Khan, Gregg C Fonarow, Darren K McGuire, Adrian F Hernandez, Muthiah Vaduganathan, Julio Rosenstock, Yehuda Handelsman, Subodh Verma, Stefan D Anker, John J V McMurray, Mikhail N Kosiborod, Javed Butler,

With worsening epidemiological trends for both the incidence and prevalence of type 2 diabetes mellitus (T2DM) and heart failure (HF) worldwide, it is critical to implement optimal prevention and treatment strategies for patients with these comorbidities, either alone or concomitantly. Several guidelines and consensus statements have recommended glucagon-like peptide-1 receptor ... Read more >>

Circulation (Circulation)
[2020, 142(12):1205-1218]

Cited: 0 times

View full text PDF listing >>



Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.

Anne L Peters, Darren K McGuire, Thomas Danne, Jake A Kushner, Helena W Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J Davies, Pablo Lapuerta,

OBJECTIVE:To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. RESEARCH DESIGN AND METHODS:Data from two identically designed, 52-week, randomized studies were pooled and analyzed for DKA, changes in β-hydroxybutyrate (BHB), and ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(11):2713-2720]

Cited: 0 times

View full text PDF listing >>



Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.

Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino, Weichung J Shih, Ira Gantz, Steven G Terra, David Z I Cherney, Darren K McGuire, ,

BACKGROUND:The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS:In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(15):1425-1435]

Cited: 1 time

View full text PDF listing >>



Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist.

Kershaw V Patel, Ashish Sarraju, Ian J Neeland, Darren K McGuire,

PURPOSE OF REVIEW:Results from cardiovascular (CV) outcome trials have revealed important insights into the CV safety and efficacy of glucose-lowering agents, including dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). RECENT FINDINGS:Among patients with T2DM, DPP-4i have no significant effect on risk of major adverse CV events (MACE: ... Read more >>

Curr Cardiol Rep (Current cardiology reports)
[2020, 22(10):105]

Cited: 0 times

View full text PDF listing >>



Medicaid Expansion and Utilization of Antihyperglycemic Therapies.

Andrew Sumarsono, Leo F Buckley, Sara R Machado, Rishi K Wadhera, Haider J Warraich, Rishi J Desai, Brendan M Everett, Darren K McGuire, Gregg C Fonarow, Javed Butler, Ambarish Pandey, Muthiah Vaduganathan,

OBJECTIVE:Certain antihyperglycemic therapies modify cardiovascular and kidney outcomes among patients with type 2 diabetes, but early uptake in practice appears restricted to particular demographics. We examine the association of Medicaid expansion with use of and expenditures related to antihyperglycemic therapies among Medicaid beneficiaries. RESEARCH DESIGN AND METHODS:We employed a difference-in-difference ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(11):2684-2690]

Cited: 0 times

View full text PDF listing >>



Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.

Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, John P H Wilding, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, Leon Litwak, Adriaan Kooy, Ingrid A M Gause-Nilsson, Martin Fredriksson, Anna Maria Langkilde, Marc S Sabatine, Itamar Raz,

AIM:To assess the associations between baseline glucose-lowering agents (GLAs) and cardiorenal outcomes with dapagliflozin versus placebo in the DECLARE-TIMI 58 study. MATERIALS AND METHODS:DECLARE-TIMI 58 assessed the cardiorenal outcomes of dapagliflozin versus placebo in patients with type 2 diabetes. This post hoc analysis elaborates the efficacy and safety outcomes by ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

Marc P Bonaca, Stephen D Wiviott, Thomas A Zelniker, Ofri Mosenzon, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, Erica L Goodrich, Remo Holanda De Mendonca Furtado, John P H Wilding, Avivit Cahn, Ingrid A M Gause-Nilsson, Per Johanson, Martin Fredriksson, Peter A Johansson, Anna Maria Langkilde, Itamar Raz, Marc S Sabatine,

BACKGROUND:Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular complications. The sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk for hospitalization for heart failure (HHF) and kidney events in patients with type 2 diabetes mellitus. An increased risk of amputation has been observed with canagliflozin in 1 ... Read more >>

Circulation (Circulation)
[2020, 142(8):734-747]

Cited: 0 times

View full text PDF listing >>



Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

Subodh Verma, Darren K McGuire, Stephen C Bain, Deepak L Bhatt, Lawrence A Leiter, C David Mazer, Tea Monk Fries, Richard E Pratley, Søren Rasmussen, Hrvoje Vrazic, Bernard Zinman, John B Buse,

Associations between body mass index (BMI) and the cardiovascular (CV) and kidney efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) are uncertain; therefore, data analysed separately from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial and the ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.187 s